Kenneth Hoberman
CIK: 0001573722
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jun 11, 2026TGTX
TG THERAPEUTICS, INC.
Award(A)DirectStock Tracking Unit
8.3K shares- - Jun 11, 2026NVCT
Nuvectis Pharma, Inc.
Award(A)Direct35K shares- - Jun 12, 2025TGTX
TG THERAPEUTICS, INC.
Award(A)Direct14.7K shares- - Jun 12, 2025NVCT
Nuvectis Pharma, Inc.
Award(A)Direct30K shares-
1-4 of 4 transactions
About Hoberman Kenneth
Hoberman Kenneth (SEC CIK 0001573722) files insider reports with the SEC as Director of TG THERAPEUTICS, INC. (TGTX) and Director of Nuvectis Pharma, Inc. (NVCT).
Signal8 holds 4 ownership filings by Hoberman Kenneth, all Form 4s, filed between Jun 12, 2025 and Jun 15, 2026. Those filings report 4 transactions, from Jun 12, 2025 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Hoberman Kenneth's filings is in FORT LEE, NJ.
Recent filings by Hoberman Kenneth
Other insiders filing for TG THERAPEUTICS, INC. (TGTX)
- Charney Laurence N, Director
- Lonial Sagar, Director
- HUME DANIEL, Director
- Echelard Yann, Director
- WEISS MICHAEL S, CEO
- Power Sean A, CFO